New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
SAN ANTONIO -- Results from two randomized phase III trials supported the use of trastuzumab deruxtecan (T-DXd; Enhertu) as a second- or third-line standard of care in patients with metastatic ...
In the article that accompanies this editorial, Rugo et al 5 review the real-world practices for the management of T-DXd–related ILD in breast cancer, providing helpful advice on strategies aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback